TCM
VRDN icon

Tradewinds Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Tradewinds Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13
Closed -$2K – 719
2017
Q4 		$2K Buy
+13
New +$1.66K ﹤0.01% 613

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tradewinds Capital Management's VRDN Position: Q1 2018 in Review

Tradewinds Capital Management sold out of Viridian Therapeutics (VRDN) in Q1 2018, closing a stake of 13 shares — an estimated $2K sold.

Tradewinds Capital Management first reported a position in VRDN in Q4 2017 and held it in 1 quarter. The position peaked at $2K in Q4 2017. 59 funds tracked by Wall St. Rank hold VRDN as of Q1 2018.

  • Tradewinds Capital Management reported no remaining Viridian Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Tradewinds Capital Management sold 13 Viridian Therapeutics shares in Q1 2018, an estimated $2K.
  • Tradewinds Capital Management first reported a position in Viridian Therapeutics in Q4 2017 and held it in 1 quarter.
  • Tradewinds Capital Management's Viridian Therapeutics position peaked at $2K in Q4 2017.
  • 59 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2018.

Based on Tradewinds Capital Management's 13F filing for Q1 2018, filed 2 May 2018.